OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY

Treatment adherence in patients with osteoporosis (OP) is rather low throughout the world, and 50 to 75% of patients stop taking anti-osteoporotic drugs within a year after therapy prescription.
Objective: to establish determinants that affect patient adherence to OP therapy.
Subjects and methods. The investigation enrolled 150 women older than 50 years (mean age, 68.8±9.4 years) with OP duration of ≥3 years who had made an outpatient visit to the V.A. Nasonova Research Institute of Rheumatology. Their examination consisted of a survey using a specially designed questionnaire. Treatment adherence was evaluated, by using the data on the duration of treatment for OP within 3 years prior to the study inclusion, as well as by calculating the drug use index.
Results and discussion. During 3 years, 94 (63%) female patients were adherent to OP treatment, including those who took zoledronic acid (78%), denosumab (75%), and alendronate or ibandronate (60%); therapy with antiosteoporotic drugs was changed in 53% of patients. The most common reason for missing or discontinuing treatment was poor drug tolerance (33%); and that for self-replacement of recommended drugs was their cost (75%). Age, education, marital status, income, duration of disease and length of treatment, a familial history of fractures or a hip fracture, the number of concomitant diseases, and the total number of drugs taken did not affect medication adherence. Patients who were more adherent to OP treatment were those who underwent determination of serum vitamin D levels (p=0.009), calculation of a 10-year absolute osteoporotic fracture risk according to the FRAX® algorithm (p=0.022), an annual bone densitometry examination (p=0.0158) and, more often than annually, biochemical blood tests (p=0.0043), as well as those who had visited their physician 3 times or more during the estimated period (p=0.003). There were more people adherent to OP treatment among the patients receiving the parenteral formulations of drugs than among those who took drugs as tablets (p=0.036). Educational materials, brochures, and lectures on OP and a follow-up in a specialized center did not ensure that treatment adherence could be significantly increased (p>0.05).
Conclusion. Patient adherence to OP therapy is positively influenced by determination of serum vitamin D levels, calculation of a 10-year absolute osteoporotic fracture risk (FRAX®), annual therapeutic monitoring using bone densitometry and results of biochemical blood tests, regular visits to a physician  who follows up the patient for OP, as well as simplification of a dosing regimen and administration of the parenteral formulations of drugs used to treat OP.

1. Liu J, Guo H, Rai P, et al. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018;29:2409-17. doi: 10.1007/s00198-018-4630-6

2. Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs – an analysis using national health databases. Osteoporos Int. 2013 Oct;24(10):2639-47. doi: 10.1007/s00198-013-2365-y

3. Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223-31. doi: 10.1007/s00198-011-1535-z

4. Liu J, Guo H, Rai P, et al. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018;29:2409-17. doi: 10.1007/s00198-018-4630-6

5. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811-8. doi: 10.1007/s00198-007-0506-x

6. Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223-31. doi: 10.1007/s00198-011-1535-z

7. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006 Jun;38(6):922-8. doi: 10.1016/j.bone.2005.10.022

8. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811-8. doi: 10.1007/s00198-007-0506-x

9. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006 Aug;81(8):1013-22. doi: 10.4065/81.8.1013

10. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006 Jun;38(6):922-8. doi: 10.1016/j.bone.2005.10.022

11. Yeam CT, Chia S, Tan HCC, et al. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis Int. 2018;29:2623-37. doi: 10.1007/s00198-018-4759-3

12. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006 Aug;81(8):1013-22. doi: 10.4065/81.8.1013

13. Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin. 2007 Oct;23(10):2369-77. doi: 10.1185/030079907X226311

14. Yeam CT, Chia S, Tan HCC, et al. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis Int. 2018;29:2623-37. doi: 10.1007/s00198-018-4759-3

15. Landfeldt E, Ström O, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012 Feb;23(2):433-43. doi: 10.1007/s00198-011-1549-6

16. Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin. 2007 Oct;23(10):2369-77. doi: 10.1185/030079907X226311

17. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW. Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med. 2013;6:839-48. doi: 10.2147/ijgm.s36944

18. Landfeldt E, Ström O, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012 Feb;23(2):433-43. doi: 10.1007/s00198-011-1549-6

19. Wade SW, Satram-Hoang S, Stolshek BS. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™. Osteoporos Int. 2014 Sep;25(9):2279-90. doi: 10.1007/s00198-014-2762-x

20. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW. Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med. 2013;6:839-48. doi: 10.2147/ijgm.s36944

21. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. doi: 10.1007/s00198-015-3164-4

22. Wade SW, Satram-Hoang S, Stolshek BS. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™. Osteoporos Int. 2014 Sep;25(9):2279-90. doi: 10.1007/s00198-014-2762-x

23. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18:1311-7. doi: 10.1007/s00198-007-0410-4

24. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. doi: 10.1007/s00198-015-3164-4

25. Hadji P, Kyvernitakis I, Kann PH, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016;27:2967-78. doi: 10.1007/s00198-016-3623-6

26. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18:1311-7. doi: 10.1007/s00198-007-0410-4

27. Dugard MN, Jones TJ, Davie MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health. 2010;64:518-22. doi: 10.1136/jech.2008.084558

28. Hadji P, Kyvernitakis I, Kann PH, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016;27:2967-78. doi: 10.1007/s00198-016-3623-6

29. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437-43. doi: 10.1592/phco.28.4.437

30. Dugard MN, Jones TJ, Davie MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health. 2010;64:518-22. doi: 10.1136/jech.2008.084558

31. Van Boven JF, de Boer PT, Postma MJ, Vegter S. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab. 2013;31:562-70. doi: 10.1007/s00774-013-0440-2

32. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437-43. doi: 10.1592/phco.28.4.437

33. Karlsson L, Lundkvist J, Psachoulia E, et al. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401-11. doi: 10.1007/s00198-015-3253-4

34. Van Boven JF, de Boer PT, Postma MJ, Vegter S. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab. 2013;31:562-70. doi: 10.1007/s00774-013-0440-2

35. Hansen C, Pedersen BD, Konradsen H, Abrahamsen B. Antiosteoporotic therapy in Denmark – predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int. 2013;24(7):2079-7. doi: 10.1007/s00198-012-2221-5

36. Karlsson L, Lundkvist J, Psachoulia E, et al. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401-11. doi: 10.1007/s00198-015-3253-4

37. Roh YH, Koh YD, Noh JH, et al. Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture. Arch Osteoporos. 2017;12(1):42. doi: 10.1007/s11657-017-0337-0

38. Hansen C, Pedersen BD, Konradsen H, Abrahamsen B. Antiosteoporotic therapy in Denmark – predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int. 2013;24(7):2079-7. doi: 10.1007/s00198-012-2221-5

39. Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1864-70. doi: 10.1002/acr.21777

40. Roh YH, Koh YD, Noh JH, et al. Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture. Arch Osteoporos. 2017;12(1):42. doi: 10.1007/s11657-017-0337-0

41. Devold HM, Furu K, Skurtveit S, et al. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297-304. doi: 10.1002/pds.2344

42. Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1864-70. doi: 10.1002/acr.21777

43. Wu X, Wei D, Sun B, Wu XN. Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis. Osteoporos Int. 2016;27(10):3083-90. doi: 10.1007/s00198-016-3763-8

44. Devold HM, Furu K, Skurtveit S, et al. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297-304. doi: 10.1002/pds.2344

45. Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 2012;50:870-5. doi: 10.1016/j.bone.2011.12.021

46. Wu X, Wei D, Sun B, Wu XN. Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis. Osteoporos Int. 2016;27(10):3083-90. doi: 10.1007/s00198-016-3763-8

47. Nikitinskaya OA, Toropcova NV, Feklistov AYu, et al. Treatment of patients with osteoporosis in actual clinical practice: issues of adherence to therapy. Osteoporoz i Osteopatii. 2015;18(1):23-7 (In Russ.).

48. Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 2012;50:870-5. doi: 10.1016/j.bone.2011.12.021

49. Clark EM, Gould VC, Tobias JH, Horne R. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study. Osteoporos Int. 2016;27(2):579-90. doi: 10.1007/s00198-015-3271-2

50. Nikitinskaya OA, Toropcova NV, Feklistov AYu, et al. Treatment of patients with osteoporosis in actual clinical practice: issues of adherence to therapy. Osteoporoz i Osteopatii. 2015;18(1):23-7 (In Russ.).

51. Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24(12):2907-18. doi: 10.1007/s00198-013-2364-z

52. Clark EM, Gould VC, Tobias JH, Horne R. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study. Osteoporos Int. 2016;27(2):579-90. doi: 10.1007/s00198-015-3271-2

53. Curtis JR, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012;64(7):1054-60. doi: 10.1002/ acr.21638

54. Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24(12):2907-18. doi: 10.1007/s00198-013-2364-z

55. Bianchi ML, Duca P, Vai S, et al. Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int. 2015;26(5):1629-38. doi: 10.1007/s00198-015-3038-9

56. Curtis JR, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012;64(7):1054-60. doi: 10.1002/ acr.21638

57. Bianchi ML, Duca P, Vai S, et al. Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int. 2015;26(5):1629-38. doi: 10.1007/s00198-015-3038-9